HIGHBuilt-in & outside partyPipeline
product candidates (no approved products)
“10-K Item 1A: 'Our business is dependent on the successful development of our current and future product candidates'”
RVMD · Concentration risk · 10-K extracted
Revolution Medicines (RVMD) concentration risks
Updated
The most significant concentration Revolution Medicines discloses is product candidates (no approved products), classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Revolution Medicines’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH2
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partySupplier
CDMOs
“10-K Item 1: 'We rely on and will continue to rely on contract development and manufacturing organizations (CDMOs) for all manufacturing activities. Currently, all of our manufacturing is outsourced'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's concentration profile is defined by two high-share exposures that are both pre-revenue and deeply interdependent: a pipeline dependency on product candidates that have yet to receive approval, and a manufacturing dependency on contract development and manufacturing organizations for all production activities. On the pipeline side, the business is dependent on the successful development of current and future product candidates, with no approved products generating commercial revenue. This is a high-share, mixed-character exposure: the concentration is structural in that it reflects the company's stage of development, but it carries the idiosyncratic risk that any single clinical or regulatory setback can meaningfully impair the value of the enterprise. With no revenue-generating asset as a buffer, the entire investment case is concentrated in development-stage outcomes. The manufacturing dependency compounds this: all manufacturing is outsourced to CDMOs, and the company relies on and will continue to rely on these contract organizations for all manufacturing activities. This is a high-share dependency in character — the company has no internal manufacturing capability, which means product supply for clinical trials and, eventually, commercialization is entirely subject to CDMO capacity, quality systems, and contractual relationships. Disruption at a key CDMO could delay clinical timelines or commercial launch. The two exposures interact directly: clinical and regulatory success on a pipeline asset will matter little if the manufacturing partner cannot produce material at the required scale and quality. Monitoring both development milestones and CDMO relationship health is therefore central to assessing execution risk for this company.
For the engine’s reasoning on RVMD’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| RVMD● | Revolution Medicines, Inc. | 2 | 0 | 0 | 2 |
| ACLX | Arcellx, Inc. | 1 | 1 | 0 | 2 |
| AGIO | Agios Pharmaceuticals, Inc. | 1 | 0 | 0 | 1 |
| ALMS | Alumis Inc. | 1 | 0 | 0 | 1 |
| ADMA | ADMA Biologics Inc | 0 | 1 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.